Deliver Your News to the World

News

Distribute Your News

  • Every day, hundreds of individuals and companies choose WebWire to distribute their news.
  • WebWire places your news within numerous highly trafficked news search engines generating leads and publicity.
  • Submit Your Release Now!

Medical / Pharmaceuticals

Releases published in the last 30 days. RSS 0.91 Feed

Page 1 of 3

Telehealth and Medicine Today Releases #ConV2X Podcast Issue
Telehealth and Medicine Today Releases #ConV2X Podcast Issue
12/13/2018 2:00:00 PM
The Telehealth and Medicine Today podcast issue spotlights the  #ConV2X  transformative technology and health modernization conference,  hosted  at Columbia University, in October.
How Does Cancer Spread?
How Does Cancer Spread?
12/12/2018 10:50:38 AM
How does cancer spread? While studying human brain tumour cells, a team of scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) found some answers to this crucial, yet so far unanswered question.
BASF raises more than $8,700 for cancer awareness and research
BASF raises more than $8,700 for cancer awareness and research
12/10/2018 12:17:47 PM
BASF employees at the Wyandotte, Michigan site recently donated more than $8,700 to the American Cancer Society to promote cancer awareness and research.
XOSPATA (gilteritinib) Available at Biologics by McKesson
XOSPATA (gilteritinib) Available at Biologics by McKesson
12/10/2018 10:30:30 AM
Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Astellas Pharma US, Inc.
Silence Therapeutics, PLC enters into 
a Settlement and 
License 
Agreement with Alnylam Pharmaceuticals
Silence Therapeutics, PLC enters into a Settlement and License Agreement with Alnylam Pharmaceuticals
12/10/2018 9:41:50 AM
Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today a Settlement and License Agreement with Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY).
Elsevier partners with health professionals to meet the challenges of data and artificial intelligence at CDSS Symposium
Elsevier partners with health professionals to meet the challenges of data and artificial intelligence at CDSS Symposium
12/10/2018 2:56:39 AM
Elsevier, the information analytics business specializing in science and health, announces the organization of a symposium dedicated to Clinical Decision Support Systems (CDSS), entitled Clinical Decision Support System, Artificial Intelligence and Big Data in the Hospital: Impacts and Limitations Seen by Physicians, and will take place at the Maison des Polytechniciens.
Company Recalls Multiple Natural and Homeopathic Health and Wellness Products due to Microbial Concerns
Company Recalls Multiple Natural and Homeopathic Health and Wellness Products due to Microbial Concerns
12/7/2018 1:09:17 PM
In October, the U.S. Food & Drug Administration (FDA) posted information from a Wisconsin company that produces natural and homeopathic products for humans and pets.
Social science research: a much-needed tool for epidemic control
Social science research: a much-needed tool for epidemic control
12/7/2018 5:10:49 AM
Zika introduced further burdens to families, often single mothers, already living in poor conditions. Research contributed to the introduction of crucial support structures.
Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer
Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer
12/7/2018 5:07:21 AM
AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients …
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics
12/6/2018 1:43:31 PM
The health care system is integrating more effective ways to leverage electronic tools to gather and use vast amounts of health-related data. These tools offer new opportunities to use data collected during the routine care of patients to advance medical care.
Advancing Orthoregeneration Through Networks, Education and Research
12/6/2018 7:45:56 AM
ON, the orthoregeneration network is an independent, internationally active foundation in the field of orthopedic tissue regeneration. A global network, education support, and innovative research are the three pillars we base our activities on.
Fujifilm Showcases Eluxeo® Platform and Supports Educational Programs at NYSGE  2018
Fujifilm Showcases Eluxeo® Platform and Supports Educational Programs at NYSGE 2018
12/6/2018 7:00:00 AM
(Booth #400) – FUJIFILM Medical Systems U.S.A., Inc. , a leading provider of endoscopic imaging solutions, will present its advanced endoscopic visualization systems at the New York Society for Gastrointestinal Endoscopy’s Annual Meeting from December 12-14, 2018 at the New York Marriott Marquis Hotel in New York, NY.
Evotec and LEO Pharma Form Drug Discovery Alliance Targeting Dermatological Conditions
Evotec and LEO Pharma Form Drug Discovery Alliance Targeting Dermatological Conditions
12/6/2018 5:13:59 AM
Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology.
Drug Innovation Ventures at Emory (DRIVE) and Antios Therapeutics Announce License for Hepatitis B Drug
Drug Innovation Ventures at Emory (DRIVE) and Antios Therapeutics Announce License for Hepatitis B Drug
12/5/2018 5:35:41 PM
Drug Innovation Ventures at Emory (DRIVE) announced the licensing of ATI-2173, its leading candidate for the treatment of hepatitis B virus (HBV), to Antios Therapeutics (Antios), a biopharmaceutical company focused on the development of novel antiviral therapies for unmet medical needs.
New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients
New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients
12/5/2018 3:06:06 PM
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced important new data from the Phase 3 CASSINI study on the use of oral anticoagulant XARELTO®  (rivaroxaban) in the management and prevention of VTE (or blood clots) in high-risk patients with cancer.
FDA Approves Removal of Boxed Warning From Regranex (Becaplermin) Gel, 0.01% as Multiple Studies Demonstrate Product Safety
FDA Approves Removal of Boxed Warning From Regranex (Becaplermin) Gel, 0.01% as Multiple Studies Demonstrate Product Safety
12/5/2018 2:18:57 PM
Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that the U.S. Food and Drug Administration (FDA) has approved the removal of the boxed warning regarding increased rate of mortality secondary to malignancy from the prescribing information of REGRANEX gel.
Are Scientists Studying the Wrong Kind of Mice?
Are Scientists Studying the Wrong Kind of Mice?
12/4/2018 5:17:16 PM
Mice represent well over half of the non-human subjects of biomedical research, and the vast majority of those mice are inbred. Formed by generation after generation of mating between brothers and sisters, inbred mice are genetically identical to each other, like twins or clones.
FDA Takes New Action to Advance the Development of Reliable and Beneficial Genetic Tests That Can Improve Patient Care
FDA Takes New Action to Advance the Development of Reliable and Beneficial Genetic Tests That Can Improve Patient Care
12/4/2018 4:31:19 PM
The U.S. Food and Drug Administration today took a significant step forward in driving the efficient development of novel diagnostic technologies that scan a person’s DNA to diagnose genetic diseases and guide medical treatments.
Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies
12/4/2018 1:31:56 PM
• Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic health records • Patients who received splenectomy, as second-line regimen, showed highest platelet counts and most frequent thrombotic event rates among groups …
Pfizer Presents Positive 26-Week Data for PF-05280586, a Potential Biosimilar to Rituximab, at The American Society of Hematology Annual Meeting
Pfizer Presents Positive 26-Week Data for PF-05280586, a Potential Biosimilar to Rituximab, at The American Society of Hematology Annual Meeting
12/4/2018 1:12:36 PM
Pfizer Inc. (NYSE:PFE) announced today at the American Society of Hematology Annual Meeting that the REFLECTIONS B328-06 study, a comparative safety and efficacy study of PF-05280586 versus Rituxan® /MabThera®  (rituximab-EU)i, met its primary endpoint of overall response rate (ORR) at Week 26 of the 52-week study.1 “It is encouraging to see new data supporting a potential …